Overexpression of ERCC1 is associated to the resistance to platinum-based chemotherapy [1], [20], [21], [22], [23], [24], which has been demonstrated in various kinds of cancers, including esophageal cancers [25], non-small cell lung cancers [26], and bladder cancers [27]. Here, ERCC1 is linked to cancer.